Full metadata record
DC FieldValueLanguage
dc.creatorBerraondo, P. (Pedro)-
dc.creatorFernandez-Sanmamed, M. (Miguel)-
dc.creatorOchoa, M.C. (María Carmen)-
dc.creatorEtxeberria, I. (Iñaki)-
dc.creatorAznar, M.A. (María Ángela)-
dc.creatorPerez-Gracia, J.L. (Jose Luis)-
dc.creatorRodriguez-Ruiz, M.E. (María Esperanza)-
dc.creatorPonz-Sarvise, M. (Mariano)-
dc.creatorCastañon, E. (Eduardo)-
dc.creatorMelero, I. (Ignacio)-
dc.date.accessioned2021-11-11T08:43:00Z-
dc.date.available2021-11-11T08:43:00Z-
dc.date.issued2019-
dc.identifier.citationBerraondo, P. (Pedro); Fernandez-Sanmamed, M. (Miguel); Ochoa, M.C. (María Carmen); et al. "Cytokines in clinical cancer immunotherapy". British Journal of Cancer. 120, 2019, 6 - 15es_ES
dc.identifier.issn1532-1827-
dc.identifier.urihttps://hdl.handle.net/10171/62531-
dc.description.abstractCytokines are soluble proteins that mediate cell-to-cell communication. Based on the discovery of the potent anti-tumour activities of several pro-inflammatory cytokines in animal models, clinical research led to the approval of recombinant interferon-alpha and interleukin-2 for the treatment of several malignancies, even if efficacy was only modest. These early milestones in immunotherapy have been followed by the recent addition to clinical practice of antibodies that inhibit immune checkpoints, as well as chimeric antigen receptor T cells. A renewed interest in the anti-tumour properties of cytokines has led to an exponential increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs. These second-generation drugs under clinical development include known molecules with novel mechanisms of action, new targets, and fusion proteins that increase half-life and target cytokine activity to the tumour microenvironment or to the desired effector immune cells. In addition, the detrimental activity of immunosuppressive cytokines can be blocked by antagonistic antibodies, small molecules, cytokine traps or siRNAs. In this review, we provide an overview of the novel trends in the cytokine immunotherapy field that are yielding therapeutic agents for clinical trials.es_ES
dc.description.sponsorshipThis work was supported by the Worldwide Cancer Research Grant under Grant 15–1146, Asociación Española Contra el Cancer (AECC) Foundation under Grant GCB15152947MELE, Red Temática de Investigacion Cooperativa en Cancer under Grants RD12/0036/0040 and RD12/0036/0062, Fondo de Investigación SanitariaFondo Europeo de Desarrollo Regional (FEDER) under Grants PI14/01686, PI13/00207 and PI16/00668, and H2020 PROCROP project under Grant 635122. P.B. is supported by Miguel Servet II (CPII15/00004) contract from Instituto de Salud Carlos III and M.F.S. is supported by a Miguel Servet (C17/00196) contract.es_ES
dc.language.isoenges_ES
dc.publisherSpringer Science and Business Media LLCes_ES
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/635122/EU-
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectCytokineses_ES
dc.subjectAnti-tumour activitieses_ES
dc.subjectInterferon-alphaes_ES
dc.subjectInterleukin-2es_ES
dc.subjectImmunotherapyes_ES
dc.titleCytokines in clinical cancer immunotherapyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.description.noteThis work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).es_ES
dc.identifier.doi10.1038/s41416-018-0328-y-
dadun.citation.endingPage15es_ES
dadun.citation.publicationNameBritish Journal of Canceres_ES
dadun.citation.startingPage6es_ES
dadun.citation.volume120es_ES

Files in This Item:
Thumbnail
File
s41416-018-0328-y.pdf
Description
Size
1.21 MB
Format
Adobe PDF


Statistics and impact

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.